lansoprazole has been researched along with Cholera Infantum in 26 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Proton pump inhibitors (PPIs) are frequently coadministered with calcineurin inhibitors (CNIs) such as tacrolimus (TAC) and cyclosporin A (CSA), to treat or prevent upper gastrointestinal complications in Japanese patients with connective tissue diseases (CTDs)." | 7.80 | The proton pump inhibitor lansoprazole, but not rabeprazole, the increased blood concentrations of calcineurin inhibitors in Japanese patients with connective tissue diseases. ( Hanafusa, T; Hata, K; Hirano-Kuwata, S; Isoda, K; Kotani, T; Makino, S; Shoda, T; Takeuchi, T; Yoshida, S, 2014) |
| "Patients enrolled in a long-term trial of lansoprazole for Zollinger-Ellison syndrome and other acid hypersecretory states had interval histories taken every six months regarding hospitalizations or other intercurrent medical conditions." | 7.74 | Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole. ( Hirschowitz, BI; Martin, T; Mohnen, J; Phadnis, M; Wilcox, CM; Worthington, J, 2008) |
| "Lafutidine could offer the possibility of more effective prevention of CT-induced mucositis through the activation of GI mucus cells." | 7.74 | Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis. ( Goso, Y; Ichikawa, T; Ikezawa, T; Ishihara, K; Iwai, T; Nakano, M; Saegusa, Y; Saigenji, K; Shikama, N, 2008) |
| " pylori-positive peptic ulcer received lansoprazole 30 mg twice daily in combination with metronidazole 400 mg twice daily and clarithromycin 250 mg twice daily for 5 days." | 5.08 | Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? ( Cunnane, K; Kelly, S; Laundon, J; McLoughlin, R; O'Connor, HJ, 1998) |
| " We report 3 cases of anaphylactic reactions induced by lansoprazole or ranitidine diagnosed in a population of 8304 first-referral patients over a 13-year period." | 4.83 | Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature. ( Bozkurt, B; Demirkan, K; Kalyoncu, AF; Karakaya, G, 2006) |
| " pylori infection, a new one-week triple therapy regimen (lansoprazole or omeprazole + amoxicillin + clarithromycin) has been approved for use in patients with peptic ulcer disease in Japan." | 4.82 | Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease. ( Hoshino, Y; Ishii, H; Kurabayashi, K; Masaoka, T; Minegishi, Y; Nomura, S; Suzuki, H; Suzuki, M, 2003) |
| "Proton pump inhibitors (PPIs) are frequently coadministered with calcineurin inhibitors (CNIs) such as tacrolimus (TAC) and cyclosporin A (CSA), to treat or prevent upper gastrointestinal complications in Japanese patients with connective tissue diseases (CTDs)." | 3.80 | The proton pump inhibitor lansoprazole, but not rabeprazole, the increased blood concentrations of calcineurin inhibitors in Japanese patients with connective tissue diseases. ( Hanafusa, T; Hata, K; Hirano-Kuwata, S; Isoda, K; Kotani, T; Makino, S; Shoda, T; Takeuchi, T; Yoshida, S, 2014) |
| "Patients enrolled in a long-term trial of lansoprazole for Zollinger-Ellison syndrome and other acid hypersecretory states had interval histories taken every six months regarding hospitalizations or other intercurrent medical conditions." | 3.74 | Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole. ( Hirschowitz, BI; Martin, T; Mohnen, J; Phadnis, M; Wilcox, CM; Worthington, J, 2008) |
| "Lafutidine could offer the possibility of more effective prevention of CT-induced mucositis through the activation of GI mucus cells." | 3.74 | Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis. ( Goso, Y; Ichikawa, T; Ikezawa, T; Ishihara, K; Iwai, T; Nakano, M; Saegusa, Y; Saigenji, K; Shikama, N, 2008) |
| " There are minor formulation-based pharmacokinetic differences among these agents, primarily reflected in their bioavailability following the first few doses." | 2.43 | Review article: similarities and differences among delayed-release proton-pump inhibitor formulations. ( Horn, JR; Howden, CW, 2005) |
| "Lansoprazole is an inhibitor of gastric acid secretion and also exhibits antibacterial activity against Helicobacter pylori in vitro." | 2.41 | Lansoprazole: an update of its place in the management of acid-related disorders. ( Jarvis, B; Matheson, AJ, 2001) |
| "Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion." | 2.40 | Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. ( Langtry, HD; Wilde, MI, 1997) |
| " Mean plasma elimination half-life (t1/2) is between 1." | 2.39 | Clinical pharmacokinetics of lansoprazole. ( Flouvat, B; Landes, BD; Petite, JP, 1995) |
| " On logistic regression analysis, none of the confounding factors (sex, age, indication, chronic use of PPI, eradication protocol) were found to contribute to the discrimination between a negative (successful eradication) and a positive (failed eradication) 13CUBT." | 1.33 | Effectiveness of omeprazole- versus lansoprazole-based triple therapy for Helicobacter pylori eradication. ( Niv, Y, 2005) |
| "To estimate the frequency of adverse events and drug interactions reported to the Food and Drug Administration in patients receiving omeprazole, lansoprazole or pantoprazole." | 1.32 | A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. ( Koelz, HR; Labenz, J; Petersen, KU; Rösch, W, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (23.08) | 18.2507 |
| 2000's | 16 (61.54) | 29.6817 |
| 2010's | 3 (11.54) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Banihani, SA | 1 |
| Khasawneh, FH | 1 |
| Isoda, K | 1 |
| Takeuchi, T | 1 |
| Kotani, T | 1 |
| Hirano-Kuwata, S | 1 |
| Shoda, T | 1 |
| Hata, K | 1 |
| Yoshida, S | 1 |
| Makino, S | 1 |
| Hanafusa, T | 1 |
| Suzuki, S | 1 |
| Gotoda, T | 1 |
| Kusano, C | 1 |
| Iwatsuka, K | 1 |
| Moriyama, M | 1 |
| Wilcox, CM | 1 |
| Martin, T | 1 |
| Phadnis, M | 1 |
| Mohnen, J | 1 |
| Worthington, J | 1 |
| Hirschowitz, BI | 1 |
| Pontone, S | 1 |
| Standoli, M | 1 |
| Angelini, R | 1 |
| Pontone, P | 1 |
| Guda, N | 1 |
| Vakil, N | 1 |
| Sawhney, MS | 1 |
| Nelson, DB | 1 |
| Labenz, J | 1 |
| Petersen, KU | 1 |
| Rösch, W | 1 |
| Koelz, HR | 1 |
| Pohland, CJ | 1 |
| Scavnicky, SA | 1 |
| Lasky, SS | 1 |
| Good, CB | 1 |
| Suzuki, H | 2 |
| Masaoka, T | 2 |
| Nomura, S | 1 |
| Hoshino, Y | 1 |
| Kurabayashi, K | 1 |
| Minegishi, Y | 1 |
| Suzuki, M | 1 |
| Ishii, H | 2 |
| Takahashi, S | 1 |
| Spiegel, BM | 1 |
| Chiou, CF | 1 |
| Ofman, JJ | 1 |
| Niv, Y | 1 |
| Sakai, G | 1 |
| Hibi, T | 1 |
| Horn, JR | 1 |
| Howden, CW | 1 |
| Konno, M | 1 |
| Demirkan, K | 1 |
| Bozkurt, B | 1 |
| Karakaya, G | 1 |
| Kalyoncu, AF | 1 |
| Saegusa, Y | 1 |
| Ichikawa, T | 1 |
| Iwai, T | 1 |
| Goso, Y | 1 |
| Ikezawa, T | 1 |
| Nakano, M | 1 |
| Shikama, N | 1 |
| Saigenji, K | 1 |
| Ishihara, K | 1 |
| Dítĕ, P | 1 |
| Prásek, J | 1 |
| Landes, BD | 1 |
| Petite, JP | 1 |
| Flouvat, B | 1 |
| Langtry, HD | 1 |
| Wilde, MI | 1 |
| Schwartz, H | 1 |
| Krause, R | 1 |
| Siepman, N | 1 |
| Haber, M | 1 |
| Weissfeld, A | 1 |
| Kidd, S | 1 |
| Rose, P | 1 |
| Sahba, B | 1 |
| O'Connor, HJ | 1 |
| McLoughlin, R | 1 |
| Kelly, S | 1 |
| Laundon, J | 1 |
| Cunnane, K | 1 |
| Bashford, JN | 1 |
| Norwood, J | 1 |
| Chapman, SR | 1 |
| Garnett, WR | 1 |
| Prescott, J | 1 |
| Matheson, AJ | 1 |
| Jarvis, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Black Seed Oil With Vonoprazan Based Triple Therapy in Treatment of Helicobacter Pylori[NCT05957432] | Phase 2 | 90 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors[NCT00204373] | Phase 4 | 72 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| A Prospective Randomized Trial of Levofloxacin-amoxicillin Triple Therapy vs. Levofloxacin-tetracycline Quadruple Therapy in Second-line Helicobacter Pylori Treatment[NCT02978157] | 102 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial[NCT02547012] | 51 participants (Actual) | Interventional | 2013-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
number of participants with control of gastric acid production (NCT00204373)
Timeframe: up to 240 months from study enrollment
| Intervention | participants (Number) |
|---|---|
| Single Group | 72 |
The median survival from the time of diagnosis (NCT00204373)
Timeframe: survival or up to 240 months
| Intervention | years (Median) |
|---|---|
| Single Group | 6.6 |
Number of participants with negative H pylori status in follow-up tests as a measure of successful eradication (NCT02978157)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo | 36 |
| Esomeprazole+Bismuth+Tetra+Levo | 49 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02547012)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo+Tetra | 13 |
| Esomeprazole+Amox+Levo | 21 |
10 reviews available for lansoprazole and Cholera Infantum
| Article | Year |
|---|---|
Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Apoptosis; Chemistry, Clinical; Clari | 2003 |
[The treatment of Helicobacter pylori infection in upper gastrointestinal disorders].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Dyspepsia; Gastritis; Gastrointes | 2003 |
Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin | 2005 |
Review article: similarities and differences among delayed-release proton-pump inhibitor formulations.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Delayed-Action Preparations; Enzyme Inhibitors; Gastrointes | 2005 |
[Helicobacter pylori eradication therapy for children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents | 2005 |
Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anaphylaxis; Anti-Ulcer Agents; Benzimidazoles; Famotidine; | 2006 |
[Proton pump blockers and their significance in gastroenterology].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Gas | 1995 |
Clinical pharmacokinetics of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aging; Anti-Ulcer Agents; Drug Interactions; Gastrointestin | 1995 |
Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis; Gastrointestinal Diseases; | 1997 |
Lansoprazole: an update of its place in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulce | 2001 |
3 trials available for lansoprazole and Cholera Infantum
| Article | Year |
|---|---|
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection: a short report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Clarithromycin; Diarrhea; Drug Administration | 1996 |
Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 1998 |
13 other studies available for lansoprazole and Cholera Infantum
| Article | Year |
|---|---|
Effect of lansoprazole on DNA integrity of human spermatozoa and activity of seminal creatine kinase.
Topics: Creatine Kinase; DNA Breaks; Gastrointestinal Diseases; Humans; Lansoprazole; Male; Proton Pump Inhi | 2020 |
The proton pump inhibitor lansoprazole, but not rabeprazole, the increased blood concentrations of calcineurin inhibitors in Japanese patients with connective tissue diseases.
Topics: Calcineurin Inhibitors; Connective Tissue Diseases; Cyclosporine; Cytochrome P-450 CYP2C19; Drug Int | 2014 |
The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Monitoring; Drug Therap | 2016 |
Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti | 2008 |
Low-dose aspirin: protection from the panacea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2002 |
An aspirin a day keeps the cardiologist away (but what about the gastroenterologist?).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aspirin; Dose-Response Relationship, Dru | 2003 |
A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adverse Drug Reaction Reporting Systems; Anti-Ulcer Agents; | 2003 |
Lansoprazole overutilization: methods for step-down therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Costs; Drug Utilization Review; Enz | 2003 |
Effectiveness of omeprazole- versus lansoprazole-based triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2005 |
Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Amoxicillin; Anti-Bacterial Agents; Anti-Ul | 2005 |
Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Animals; Anti-Ulcer Agents; Antimetabolites, An | 2008 |
Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Prescriptions; Family Practice; Gas | 1998 |
Coprescribing proton pump inhibitors with other medications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Drug Interactions; Drug Prescriptions; Enzyme Inhibi | 2000 |